Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19
COVID-19
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring COVID-19, lactoferrin
Eligibility Criteria
Inclusion Criteria:
- Positive reverse-transcriptase-polymerase chain- reaction (RT-PCR) assay for SARS- CoV-2 in a respiratory tract sample.
Exclusion Criteria:
- Known allergy or hypersensitivity to the used medications
- Severe symptoms: respiratory insufficiency that requires admission in intensive care unit or mechanical ventilation
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Standard of care in addition to 400 mg lactoferrin
Standard of care in addition to 600 mg lactoferrin
Standard of care only
Standard of care treatment; as per MOHP protocol, in addition to 400 mg oral lactoferrin daily [two sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
Standard of care treatment; as per MOHP protocol, in addition to 600 mg oral lactoferrin daily [three sachets 100 mg granules (Pravotin sachets, Hygint, Egypt) in 1/4 glass of water twice a day before meals]
Standard of care treatment; as per MOHP protocol